Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Therma Bright Inc (OP: TBRIF )

0.0355 -0.0011 (-3.01%)
Streaming Delayed Price Updated: 3:46 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,910
Open 0.0380
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0366
Today's Range 0.0355 - 0.0414
52wk Range 0.0040 - 0.0746
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Therma Bright Investment Portfolio Company InStatin Secures Mountain West Research Discovery Study Agreement
Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a... 
Via Newsfile
Therma Bright Welcomes Medical Device & Pharmaceutical Veteran Douglas S. Sommerville to Its Advisory Board
Toronto, Ontario--(Newsfile Corp. - September 12, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a... 
Via Newsfile
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension

Performance

YTD
+610.00%
+610.00%
1 Month
-35.34%
-35.34%
3 Month
+234.91%
+234.91%
6 Month
+787.50%
+787.50%
1 Year
+29.56%
+29.56%

More News

Read More
This Company Is Betting On Innovation To Make A Splash In Multiple Healthcare Markets And It Hit Multiple Milestones This Year
Via News Direct
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF): Major Approvals Make TBRIF A Stock To Watch
Via AB Newswire
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF): Major Approvals Make TBRIF A Stock To Watch
Via News Direct
Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Via Newsfile
Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial Success
Via Newsfile
RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Via Newsfile
Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Via Newsfile
Therma Bright's Venowave VW5 Secures Permanent HCPCS Code E0683 from U.S. DHHS's Centers for Medicare & Medicaid Services
Via Newsfile
Therma Bright's AI-Powered Digital Cough Technology Being Considered as Partner Technology in New Chronic Cough Drug Clinical Trial
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
Via Newsfile
Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM): Pioneering Growth in the Expanding Medical Devices Market
Via AB Newswire
Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM): Pioneering Growth in the Expanding Medical Devices Market
Via News Direct
Therma Bright Expands InStatin Investment
Via Newsfile
Therma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Via Newsfile
Therma Bright's Venowave VW5 Secures FDA 510K Approval
Via Newsfile
Exposures Product Safety
Therma Bright Engages Independent Trading Group as Market Maker
Via Newsfile
Therma Bright Q2, 2024 Market Update On Business
Via Newsfile
Therma Bright Completes Debt Settlements
Via Newsfile
Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer
Via AB Newswire
Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer
Via TheNewswire.com
Exposures Product Safety
Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer
Via News Direct
Exposures Product Safety
Therma Bright Closes $854,500 First Tranche of Non-Brokered Private Placement
Via Newsfile
Therma Bright Announces Strategic Review & Update on Investment in Inretio
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.